Cwm LLC Sells 159,648 Shares of Mersana Therapeutics, Inc. $MRSN

Cwm LLC decreased its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN) by 96.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,756 shares of the company’s stock after selling 159,648 shares during the period. Cwm LLC’s holdings in Mersana Therapeutics were worth $44,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in MRSN. JPMorgan Chase & Co. boosted its stake in Mersana Therapeutics by 156.6% during the second quarter. JPMorgan Chase & Co. now owns 130,094 shares of the company’s stock valued at $39,000 after buying an additional 79,390 shares during the last quarter. Invesco Ltd. boosted its position in shares of Mersana Therapeutics by 109.3% during the 1st quarter. Invesco Ltd. now owns 114,863 shares of the company’s stock valued at $40,000 after acquiring an additional 59,991 shares during the last quarter. Marshall Wace LLP purchased a new position in shares of Mersana Therapeutics in the second quarter valued at $68,000. Cerity Partners LLC grew its holdings in shares of Mersana Therapeutics by 31.4% in the second quarter. Cerity Partners LLC now owns 320,805 shares of the company’s stock valued at $95,000 after purchasing an additional 76,570 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in Mersana Therapeutics in the second quarter worth $151,000. 93.92% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have commented on MRSN. Wedbush lowered shares of Mersana Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 13th. William Blair cut shares of Mersana Therapeutics from a “strong-buy” rating to a “market perform” rating in a research report on Thursday, November 13th. Guggenheim lowered Mersana Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 14th. Wall Street Zen raised Mersana Therapeutics to a “sell” rating in a research note on Saturday, January 10th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mersana Therapeutics in a research note on Monday, December 29th. Seven equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average target price of $38.19.

Mersana Therapeutics Stock Performance

Shares of NASDAQ MRSN opened at $29.08 on Thursday. The business’s 50 day moving average price is $28.42 and its 200-day moving average price is $15.15. Mersana Therapeutics, Inc. has a fifty-two week low of $5.21 and a fifty-two week high of $36.25. The company has a market cap of $145.37 million, a price-to-earnings ratio of -2.10 and a beta of 0.44.

Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Friday, November 14th. The company reported ($1.51) EPS for the quarter, missing the consensus estimate of ($1.44) by ($0.07). The business had revenue of $11.01 million during the quarter, compared to the consensus estimate of $14.20 million. Sell-side analysts predict that Mersana Therapeutics, Inc. will post -0.62 earnings per share for the current year.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development of innovative antibody-drug conjugates (ADCs) for the treatment of cancer. Since its founding in 2003, Mersana has leveraged its proprietary Fleximer® platform to engineer next-generation ADCs that aim to improve the therapeutic index by enhancing drug delivery to tumor cells while minimizing systemic toxicity. The company’s research efforts are centered on creating highly potent payloads linked to antibodies that selectively target tumor-associated antigens.

The Fleximer platform enables site-specific conjugation of multiple payload molecules, offering adjustable drug-to-antibody ratios and controlled release characteristics.